Loading provider…
Loading provider…
Dermatology Physician in Sunnyvale, CA
NPI: 1245299379Primary Employer
Palo Alto Medial Foundation
sutterhealth.org
HQ Phone
Get MD Amit's Phone Numberphone_androidMobile
Get MD Amit's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
CA State Medical License
CA State Medical License
2019 - 2027
TX State Medical License
1986 - 2023

American Board of Dermatology
Dermatology

American Board of Internal Medicine
Internal Medicine
University of Texas Southwestern Medical Center
Residency • Dermatology
1988 - 1991
Texas Health Resources (Dallas)
Residency • Internal Medicine
1985 - 1988
UT Southwestern Medical Center
utsouthwestern.edu
Medical School
Until 1985
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 36 | 53 |
| 2 | 96900Application of ultraviolet light to skin | 29 | 467 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 24 | 37 |
Successful Treatment of Sézary Syndrome With Lymphomatous Transformation to Large Cell Lymphoma With Fludarabine Phosphate
Authors: Cynthia Rutherford, Anthony Nikko
Publication Date: 1996-08
Time for a patient-oriented outcome in vitiligo: the vitiligo noticeability scale.
Authors: Khaled Ezzedine, Amit G. Pandya
Publication Date: 2016-02
Authors: Paul Bergstresser, Isha Lopez, Jessica Dietert, Nnenna Agim, Kara Pretzlaff, Stephanie Savory, Tiffany Lieu, Travis Vandergriff
Journal: J Am Acad Dermatol
Publication Date: 2013-10-28
Lead Sponsor: University of Texas Southwestern Medical Center
Collaborators: Children's Medical Center Dallas
Intervention / Treatment: OTHER: Water, OTHER: Dilute bleach baths
Lead Sponsor: Kemia, Inc
Intervention / Treatment: DRUG: KC706
Lead Sponsor: Jacobus Pharmaceutical
Intervention / Treatment: DRUG: Dapsone